Montelukast Inhibits Matrix Metalloproteinases Expression in Atherosclerotic Rabbits

@article{Liu2009MontelukastIM,
  title={Montelukast Inhibits Matrix Metalloproteinases Expression in Atherosclerotic Rabbits},
  author={Dezhi Liu and Song Ge and Guangyi Zhou and Gelin Xu and Renliang Zhang and Wusheng Zhu and Zhenguo Liu and S. Cheng and Xinfeng Liu},
  journal={Cardiovascular Drugs and Therapy},
  year={2009},
  volume={23},
  pages={431-437}
}
BackgroundMatrix metalloproteinases (MMPs) play important roles in the development and destabilization of atherosclerotic plaques. It is known that montelukast inhibits neointimal hyperplasia. However, the underlying mechanisms for the inhibitory effects of montelukast on neointimal formation have been poorly defined.MethodsThirty-six male New Zealand White rabbits were randomized as normal control, placebo (0.9% NaCl, 1.5 ml/kg/day, via intraperitoneal injection), atorvastatin (atorvastatin, 1… Expand
Montelukast, a Cysteinyl Leukotriene Receptor 1 Antagonist, Induces M2 Macrophage Polarization and Inhibits Murine Aortic Aneurysm Formation
TLDR
Montelukast induces M2 macrophage polarization and prevents AAA formation in apoE−/− mice and significantly decreased aortic expansion in vivo. Expand
Monteleucast and Zileuton Retard the Progression of Atherosclerosis via Down Regulation of the Inflammatory and Oxidative Pathways
TLDR
Both montelukast and zileuton reduce lipid peroxidation, systemic inflammation and aortic expressions of inflammatory markers used in this study and reduced the progression of atherosclerosis. Expand
Effect of montelukast on progression of atherosclerosis
TLDR
Evaluating the effect of montelukast on the progression of atherosclerosis and histopathologic assessment of aortic atherosclerotic changes was undertaken. Expand
Matrix metalloproteinases in atherosclerosis: role of nitric oxide, hydrogen sulfide, homocysteine, and polymorphisms
TLDR
The purpose of this review is to examine the role of MMPs and their polymorphisms on the development of atherosclerosis, with emphasis placed on pathways that involve nitric oxide, hydrogen sulfide, and homocysteine. Expand
The leukotriene receptor antagonist montelukast and its possible role in the cardiovascular field
TLDR
The aims of this short review are to delineate the potential cardiovascular protective role of a LTRA, montelukast, beyond its traditional use, and to foster the design of appropriate clinical trials to test this hypothesis. Expand
The leukotrienes: immune-modulating lipid mediators of disease.
TLDR
The most recent understanding of the leukotriene cascade is reviewed with emphasis on recently identified roles in immune reactions and pathophysiology. Expand
Zafirlukast Is a Dual Modulator of Human Soluble Epoxide Hydrolase and Peroxisome Proliferator-Activated Receptor γ
TLDR
Zafirlukast is a novel dual sEH/PPARγ modulator representing an excellent starting point for the further development of this compound class andhibits antagonistic activities concerning recruitment of the PPARγ cofactor CBP upon ligand binding. Expand
Potential role of leukotriene receptor antagonists in reducing cardiovascular and cerbrovascular risk: A systematic review of human clinical trials and in vivo animal studies.
TLDR
All animal studies reported that using a leukotriene receptor antagonist brings to a reduction of either myocardial infarction, ischemic stroke, or atherosclerosis risk, suggesting a potential role of montelukast in reducing some cardiovascular diseases. Expand
Cysteinyl‐leukotriene pathway as a new therapeutic target for the treatment of atherosclerosis related to obstructive sleep apnea syndrome
TLDR
In the era of personalized medicine, U‐LTE4 may be a useful biomarker to identify OSA patients for whom CysLT1 blockade could represent a new therapeutic avenue for reducing cardiovascular risk. Expand
Montelukast: The New Therapeutic Option for the Treatment of Epilepsy
TLDR
The present review summarizes the neuropharmacological actions of montelukast in epilepsy with an emphasis on the recent findings associated with CysLT and cell-specific effects. Expand
...
1
2
...

References

SHOWING 1-10 OF 39 REFERENCES
A matrix metalloproteinase inhibitor, ONO-4817, suppresses the development of aortic intimal hyperplasia in experimental hyperlipidemic rabbit.
TLDR
Evidence is reported that an MMPi can suppress the development of intimal hyperplasia in hyperlipidemic rabbits for the first reported evidence that a broad-spectrum MMP inhibitor can suppress this condition. Expand
Anti-atherogenic effects of montelukast associated with reduced MCP-1 expression in a rabbit carotid balloon injury model.
TLDR
The results suggest that montelukast produces anti-atherogenic effects unrelated to plasma lipid modulation but related to MCP-1 down regulation. Expand
Deficiency of Gelatinase A Suppresses Smooth Muscle Cell Invasion and Development of Experimental Intimal Hyperplasia
TLDR
In a mouse carotid artery blood flow cessation model, MMP-2 contributes to intimal hyperplasia mainly through the SMC migration from the media into the intima by degrading and breaching the extracellular matrix proteins surrounding each cell and the internal elastic lamina. Expand
Effect of broad-spectrum matrix metalloproteinase inhibition on atherosclerotic plaque stability.
TLDR
The data suggest that broad-spectrum MMP inhibition RS-130830 does not have a beneficial effect on atherosclerosis in the apolipoprotein E knockout mouse model, and indicate that more selective compounds would be preferable. Expand
Immunolocalization of matrix metalloproteinases in rabbit carotid arteries after balloon denudation
TLDR
The results suggest that all MMPs act in coordination to promote replication and migration ofSMCs in the earlier phases of neointimal formation and that MMP-2 independently contributes to the later stages by facilitating the migration but not replication of SMCs from the media to the intima. Expand
Differential Effects of Doxycycline, a Broad-Spectrum Matrix Metalloproteinase Inhibitor, on Angiotensin II–Induced Atherosclerosis and Abdominal Aortic Aneurysms
TLDR
These data do not imply a role for MMPs in AngII-induced atherosclerosis but provide evidence consistent with a role in Ang II-induced AAA formation, and doxycycline markedly reduced the incidence of AAA formation. Expand
Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly.
TLDR
Experimental evidence acquired in vitro and in vivo suggests that the major drivers of vascular remodeling, hemodynamics, injury, inflammation, and oxidative stress, regulate MMP expression and activity, and nonspecific MMP inhibition seems to oppose remodeling. Expand
Role of cysteinyl leukotrienes in the proliferation and the migration of murine vascular smooth muscle cells in vivo and in vitro.
TLDR
The data suggest that Cys-LTs are involved in VSMC proliferation and migration, and a Cys -LT receptor antagonist may have beneficial effects on vascular remodeling after mechanical injury. Expand
Montelukast regulates eosinophil protease activity through a leukotriene-independent mechanism.
TLDR
Montelukast inhibits eosinophil protease activity in vitro through a mechanism that might be independent of its antagonist effect on CysLT 1 receptor, which could partially explain montelukasta's anti-inflammatory effect in asthma and eventually amplify to improve its therapeutic efficacy. Expand
Matrix metalloproteinases, inflammation and atherosclerosis: therapeutic perspectives
Abstract Matrix metalloproteinases (MMPs), also called matrixins, are proteinases that participate in extracellular matrix remodelling and degradation. Under normal physiological conditions, theExpand
...
1
2
3
4
...